Clinical Trials | September 26, 2025
BIL also holds an option to increase its equity stake by an additional 15%
The expansion, supported by a significant UK government grant, includes a new lipid system synthesis facility and enhanced R&D capabilities
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
This predictive technology empowers people with diabetes to take preventive action before complications arise
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
Launches National IVD validation portal and protocols; highlights India’s strengthening health research ecosystem
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
A new medical-grade Amodel PPA delivers high heat resistance, electrically insulative properties, and biocompatibility for advanced single-use medical instruments and assemblies
Subscribe To Our Newsletter & Stay Updated
